James Whelan speaks with Jayne Shaw, Non-Executive Chair of BCAL Diagnostics (ASX: BDX), about the company’s move from research and development to commercialising blood-based cancer tests.
Shaw discusses BREASTESTplus alongside mammography, GP referral infrastructure, clinician education and BCAL’s licensed Avantect tests. She also explains the team’s focus on test sales and commercial execution under CEO Anne-Louise (Annie) Arnett.
Management’s plans discussed in this interview include a November 2026 BREASTESTplus update, US validation work with Sonic Healthcare and an MSAC reimbursement application for pancreatic testing. Planned development, validation and reimbursement steps remain conditional.
Recorded 26 October 2026. Diagnostic tests require clinical interpretation and follow-up and do not replace established screening or medical advice.
For more interviews, visit smallcaps.com.au.
This content is for information only and is not financial or medical advice.
Chapters 0
